학술논문

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Document Type
article
Author
Johnatty, Sharon EGroup, on behalf of the Australian Ovarian Cancer StudyTyrer, Jonathan PKar, SiddharthaBeesley, JonathanLu, YiGao, BoFasching, Peter AHein, AlexanderEkici, Arif BBeckmann, Matthias WLambrechts, DietherVan Nieuwenhuysen, ElsVergote, IgnaceLambrechts, SandrinaRossing, Mary AnneDoherty, Jennifer AChang-Claude, JennyModugno, FrancesmaryNess, Roberta BMoysich, Kirsten BLevine, Douglas AKiemeney, Lambertus AMassuger, Leon FAGGronwald, JacekLubiński, JanJakubowska, AnnaCybulski, CezaryBrinton, LouiseLissowska, JolantaWentzensen, NicolasSong, HonglinRhenius, ValerieCampbell, IanEccles, DianaSieh, WeivaWhittemore, Alice SMcGuire, ValerieRothstein, Joseph HSutphen, RebeccaAnton-Culver, HodaZiogas, ArgyriosGayther, Simon AGentry-Maharaj, AleksandraMenon, UshaRamus, Susan JPearce, Celeste LPike, Malcolm CStram, Daniel OWu, Anna HKupryjanczyk, JolantaDansonka-Mieszkowska, AgnieszkaRzepecka, Iwona KSpiewankiewicz, BeataGoodman, Marc TWilkens, Lynne RCarney, Michael EThompson, Pamela JHeitz, Floriandu Bois, AndreasSchwaab, IraHarter, PhilippPisterer, JacobusHillemanns, PeterGroup, on behalf of the AGO StudyKarlan, Beth YWalsh, ChristineLester, JennyOrsulic, SandraWinham, Stacey JEarp, MadaleneLarson, Melissa CFogarty, Zachary CHøgdall, EstridJensen, AllanKjaer, Susanne KrugerFridley, Brooke LCunningham, Julie MVierkant, Robert ASchildkraut, Joellen MIversen, Edwin STerry, Kathryn LCramer, Daniel WBandera, Elisa VOrlow, IrenePejovic, TanjaBean, YukieHøgdall, ClausLundvall, LeneMcNeish, IanPaul, JamesCarty, KarenSiddiqui, NadeemGlasspool, RosalindSellers, ThomasKennedy, CatherineChiew, Yoke-EngBerchuck, AndrewMacGregor, StuartPharoah, Paul DP
Source
Clinical Cancer Research. 21(23)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Orphan Drug
Clinical Research
Rare Diseases
Genetics
Ovarian Cancer
Cancer
Human Genome
2.1 Biological and endogenous factors
Aetiology
Alleles
Carcinoma
Ovarian Epithelial
Computational Biology
Female
Genome-Wide Association Study
Genotype
Humans
Kaplan-Meier Estimate
Meta-Analysis as Topic
Neoplasms
Glandular and Epithelial
Ovarian Neoplasms
Patient Outcome Assessment
Polymorphism
Single Nucleotide
Prognosis
Quantitative Trait Loci
AGO Study Group
Australian Ovarian Cancer Study Group
Oncology & Carcinogenesis
Clinical sciences
Oncology and carcinogenesis
Language
Abstract
PurposeChemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome.Experimental designWe analyzed approximately 2.8 million genotyped and imputed SNPs from the iCOGS experiment for progression-free survival (PFS) and overall survival (OS) in 2,901 European epithelial ovarian cancer (EOC) patients who underwent first-line treatment of cytoreductive surgery and chemotherapy regardless of regimen, and in a subset of 1,098 patients treated with ≥ 4 cycles of paclitaxel and carboplatin at standard doses. We evaluated the top SNPs in 4,434 EOC patients, including patients from The Cancer Genome Atlas. In addition, we conducted pathway analysis of all intragenic SNPs and tested their association with PFS and OS using gene set enrichment analysis.ResultsFive SNPs were significantly associated (P ≤ 1.0 × 10(-5)) with poorer outcomes in at least one of the four analyses, three of which, rs4910232 (11p15.3), rs2549714 (16q23), and rs6674079 (1q22), were located in long noncoding RNAs (lncRNAs) RP11-179A10.1, RP11-314O13.1, and RP11-284F21.8, respectively (P ≤ 7.1 × 10(-6)). ENCODE ChIP-seq data at 1q22 for normal ovary show evidence of histone modification around RP11-284F21.8, and rs6674079 is perfectly correlated with another SNP within the super-enhancer MEF2D, expression levels of which were reportedly associated with prognosis in another solid tumor. YAP1- and WWTR1 (TAZ)-stimulated gene expression and high-density lipoprotein (HDL)-mediated lipid transport pathways were associated with PFS and OS, respectively, in the cohort who had standard chemotherapy (pGSEA ≤ 6 × 10(-3)).ConclusionsWe have identified SNPs in three lncRNAs that might be important targets for novel EOC therapies.